| Previous Close | 35.96 |
| Open | 35.90 |
| Bid | 35.81 x 2100 |
| Ask | 35.82 x 9500 |
| Day's Range | 35.74 - 36.03 |
| 52 Week Range | 29.83 - 36.21 |
| Volume | 5,885,002 |
| Avg. Volume | 16,874,860 |
| Market Cap | 212.62B |
| Beta | 1.06 |
| PE Ratio (TTM) | 26.15 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.61%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- American City Business Journals•53 minutes ago
Pfizer helps pump $103M into startup to develop new cancer therapies
A local startup has been spun-out of Pfizer to develop clinical-stage experimental therapies. Nascent medicine company SpringWorks Therapeutics completed a $103 million series A round led by the New York-based pharma giant with the help of Bain Capital, OrbiMed and LifeArc (formerly known as MRC Technology). Pfizer (PFE) granted SpringWorks the rights to help develop four drugs or therapies that treat various conditions, including post-traumatic stress disorder and cancer.
- Bloomberg•2 hours ago
Pfizer Channels Its Inner Biotech
Four pipeline castoffs should fetch a higher valuation standing alone.
Markit•5 hours agoSee what the IHS Markit Score report has to say about Pfizer Inc.
Pfizer Inc NYSE:PFE
